Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -86.36% | 6,357.14% | 3,704.35% | 40,400.00% | 41.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -86.36% | 6,357.14% | 3,704.35% | 40,400.00% | 41.03% |
| Cost of Revenue | -80.00% | -- | 471.43% | -44.94% | 29.03% |
| Gross Profit | -89.86% | 14,966.67% | 5,118.75% | 1,471.76% | 46.81% |
| SG&A Expenses | -6.00% | -34.60% | 25.75% | 64.18% | -27.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.58% | -34.62% | 26.39% | 61.59% | -27.47% |
| Operating Income | 4.83% | 37.10% | -8.95% | -29.24% | 28.24% |
| Income Before Tax | -26.98% | 181.70% | 399.62% | -639.67% | 60.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.98% | 181.70% | 399.62% | -639.67% | 60.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.98% | 181.70% | 399.62% | -639.67% | 60.40% |
| EBIT | 4.83% | 37.10% | -8.95% | -29.24% | 28.24% |
| EBITDA | 7.16% | 40.77% | -13.46% | -51.49% | 36.83% |
| EPS Basic | 33.33% | 139.89% | 194.43% | -309.51% | 83.04% |
| Normalized Basic EPS | 57.89% | 136.07% | 195.70% | -309.31% | 72.86% |
| EPS Diluted | 33.33% | 96.00% | 99.02% | -309.51% | 83.04% |
| Normalized Diluted EPS | 57.89% | 107.38% | 113.98% | -309.31% | 72.86% |
| Average Basic Shares Outstanding | 94.27% | 105.66% | 218.15% | 157.65% | 131.70% |
| Average Diluted Shares Outstanding | 94.27% | 905.31% | 2,106.33% | 157.65% | 131.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
